Compare ORN & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORN | STTK |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.4M | 538.3M |
| IPO Year | 2007 | 2020 |
| Metric | ORN | STTK |
|---|---|---|
| Price | $15.81 | $4.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $16.25 | $10.00 |
| AVG Volume (30 Days) | 336.1K | ★ 972.9K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 53.02 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $852,260,000.00 | $1,000,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $127.58 | ★ N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $6.44 | $0.71 |
| 52 Week High | $15.85 | $8.33 |
| Indicator | ORN | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 65.36 | 45.13 |
| Support Level | $13.20 | $3.37 |
| Resistance Level | $15.83 | $6.81 |
| Average True Range (ATR) | 0.74 | 0.58 |
| MACD | 0.15 | 0.05 |
| Stochastic Oscillator | 91.67 | 58.54 |
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada, and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment generates maximum revenue and provides construction services for commercial, industrial, multi-family residential, and public projects, including the data center market.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.